Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Characterization of bleomycin-resistant DNA.

M Tien Kuo, C W Haidle, L D Inners

    Biophysical Journal
    |December 1, 1973
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines.

    Biochemical and biophysical research communications·2010
    Same author

    Roles of multidrug resistance genes in breast cancer chemoresistance.

    Advances in experimental medicine and biology·2007
    Same author

    Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers.

    Molecular carcinogenesis·2006
    Same author

    Molecular cloning of Chinese hamster 1q31 chromosomal fragile site DNA that is important to mdr1 gene amplification reveals a novel gene whose expression is associated with spermatocyte and adipocyte differentiation.

    Gene·2006
    Same author

    Association of fragile site-associated (FSA) gene expression with epithelial differentiation and tumor development.

    Biochemical and biophysical research communications·2006
    Same author

    Procollagen alpha 1 type 1: a potential aide in histopathological grading of glioma.

    Cancer investigation·2005

    Bleomycin treatment degrades DNA, leaving a resistant fraction. This bleomycin-resistant DNA is single-stranded, small (4,000 daltons), and does not interact with the drug.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Pharmacology

    Background:

    • Bleomycin is an anticancer drug known to degrade DNA.
    • Understanding DNA-drug interactions is crucial for developing effective cancer therapies.

    Purpose of the Study:

    • To characterize the nature of DNA that remains resistant to bleomycin treatment.
    • To investigate the properties of bleomycin-resistant DNA.

    Main Methods:

    • Treatment of native DNA with high concentrations of bleomycin.
    • Analysis of trichloroacetic acid (TCA) soluble and insoluble fractions.
    • Assessing drug interaction through competition assays.
    • Determining DNA structure via hyperchromicity and melting temperature analysis.
    • Molecular weight determination using sedimentation and equilibrium analyses.

    Related Experiment Videos

    Main Results:

    • Approximately 80% of DNA becomes TCA soluble after bleomycin treatment, while 20% remains TCA insoluble.
    • The TCA-insoluble fraction, termed bleomycin-resistant DNA, is not further degraded by the drug.
    • Bleomycin-resistant DNA does not compete with native DNA for bleomycin binding, indicating no drug inactivation.
    • Resistant DNA exhibits a single-stranded structure with minimal hyperchromicity.
    • Sedimentation and equilibrium analyses reveal a molecular weight of approximately 4,000 daltons for resistant DNA.
    • The base composition of resistant DNA is similar to its native DNA source.

    Conclusions:

    • A distinct fraction of DNA is resistant to bleomycin-induced degradation.
    • Bleomycin-resistant DNA possesses unique structural and molecular characteristics, including single-strandedness and a low molecular weight.
    • These findings contribute to understanding bleomycin's mechanism of action and DNA repair pathways.